Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. BioNTech SE
  6. News
  7. Summary
    BNTX   US09075V1026

BIONTECH SE

(BNTX)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

US' CDC To Study Possible Link Between Heart Inflammation And Pfizer/BioNTech, Moderna Vaccines

06/23/2021 | 11:49am EDT


© MT Newswires 2021
All news about BIONTECH SE
03:02pBIONTECH : Completes Acquisition of Gilead Subsidiary's Neoantigen TCR Cell Ther..
MT
11:14aEuropean ADRs Move Slightly Higher in Wednesday Trading
MT
10:58aGLOBAL MARKETS LIVE : Novartis, Apple, Commerzbank, Amgen, Lyft...
10:23aPFIZER : South Africa quickens vaccine drive, gets more doses from US
AQ
07:46aBIONTECH : completes Acquisition of Kite's Neoantigen TCR Cell Therapy R&D Platf..
PU
07:28aMARKET CHATTER : Thonburi Healthcare Faces Regulatory Pressure on Purported Vacc..
MT
07:21aBIONTECH : Completes Cell Therapy Platform, Facility Purchase From Gilead Unit
MT
07:00aBIONTECH : Completes Acquisition of Kite's Neoantigen TCR Cell Therapy R&D Platf..
AQ
07:00aPRESS RELEASE : BioNTech Completes Acquisition of Kite's Neoantigen TCR Cell The..
DJ
03:10aThai hospital tycoon who promised Pfizer vaccine says deal now unlikely
RE
More news
Financials
Sales 2021 13 071 M 15 467 M 15 467 M
Net income 2021 7 590 M 8 981 M 8 981 M
Net cash 2021 8 581 M 10 154 M 10 154 M
P/E ratio 2021 11,6x
Yield 2021 -
Capitalization 84 562 M 100 B 100 B
EV / Sales 2021 5,81x
EV / Sales 2022 5,94x
Nbr of Employees 2 200
Free-Float 87,3%
Chart BIONTECH SE
Duration : Period :
BioNTech SE Technical Analysis Chart | BNTX | US09075V1026 | MarketScreener
Technical analysis trends BIONTECH SE
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 12
Last Close Price 350,12 €
Average target price 165,41 €
Spread / Average Target -52,8%
EPS Revisions
Managers and Directors
Ugur Sahin Chief Executive Officer
Jens Holstein Chief Financial Officer
Helmut Jeggle Chairman-Supervisory Board
Özlem Türeci Chief Medical Officer
Sierk Pötting Chief Operating Officer
Sector and Competitors
1st jan.Capi. (M$)
BIONTECH SE408.39%84 970
GILEAD SCIENCES, INC.17.32%87 579
WUXI APPTEC CO., LTD.41.52%71 929
REGENERON PHARMACEUTICALS19.46%60 737
VERTEX PHARMACEUTICALS-15.36%51 899
BEIGENE, LTD.32.15%31 737